Biotech

Biotechnology, gene editing, biopharma platforms, and clinical pipelines.

  • 9 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Biotech


manufacturingchemist.com > malvern-panalytical-launches-zetasizer-core-for-biologics-stability

Malvern Panalytical launches Zetasizer Core for biologics stability screening

28+ min ago   (259+ words) New instrument combines DLS, SLS and DSF on standard well plates Three distinct capabilities set the Zetasizer Core apart: The result is a platform that consolidates three measurements into a single run, giving formulation teams the evidence to distinguish a…...


fundssociety.com > en > news > markets > mrna-melanoma-vaccine-what-the-market-measures-and-how-health-managers-interpret-it

mRNA Melanoma Vaccine Market Reaction and Outlook

6+ min ago   (162+ words) Date: 15 Sep 2026 · 16:32 The next real test for all of this comes in October, with the European Society for Medical Oncology (ESMO) Congress, taking place from October 23 to 27 in Madrid. It is one of the most influential events on the global…...


finance.yahoo.com > healthcare > articles > definium-reports-second-phase-iii-141600164.html

Definium Reports Second Phase III Success in Anxiety Disorder Program

23+ min ago   (353+ words) Year to date, Definium stock has skyrocketed 200.6% against the industry's 2.9% decline. Beyond GAD, Definium is advancing DT120 ODT in major depressive disorder (MDD). DFTX's phase III Emerge study delivered positive top-line results in June 2026, meeting its primary and key secondary endpoints. The…...


citybiz.co > article > 903218 > nix-biosensors-raises-10-million-series-a-to-expand-hydration-intelligence-platform

Nix Biosensors Raises $10 Million Series A to Expand Hydration Intelligence Platform

24+ min ago   (693+ words) Nix Biosensors has closed a $10 million Series A funding round to expand its hydration monitoring technology and bring its personalized hydration data into consumer health platforms, increasing the company’s total funding to $17 million. Investors include Shorewind Capital, Great Oaks Venture…...


marketscreener.com > news > investor-determination-to-beat-cancer-puts-neonca-s-novel-therapies-and-patented-platform-in-focus-ce785bdddc8df324

Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus

45+ min ago   (573+ words) Published on 09/15/2026 at 09:54 am EDT DALLAS, Sept. 15, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- The Chief Executive Officer of NeOnc Technologies Holdings (NASDAQ:NTHI), Amir F. Heshmatpour has purchased another 37,000 shares of the company’s common stock, adding to his investment following NeOnc’s announcement…...


tradingpedia.com > 09/15/2026 > rocket-pharma-rallies-as-fda-backs-key-danon-trial-plan

Rocket Pharma Rallies as FDA Backs Key Danon Trial Plan

48+ min ago   (289+ words) Investing.com — Rocket Pharmaceuticals (NASDAQ:RCKT) saw its share price advance 8% on Tuesday after the company reported that it had reached alignment with the U.S. Food and Drug Administration on the pivotal Phase 2 clinical trial of RP-A501 for Danon disease....


tradingview.com > news > urn:summary_document_transcript:quartr.com:4170987:0-rxrx-ai-driven-drug-discovery-engine-delivers-first-in-class-assets-and-strong-partnership-milestones

RXRX: AI-driven drug discovery engine delivers first-in-class assets and strong partnership milestones

1+ hour, 2+ min ago   (66+ words) TradingView RXRX: AI-driven drug discovery engine delivers first-in-class assets and strong partnership milestones The conference highlighted a strategic transformation to an AI-driven, end-to-end drug discovery engine, with significant cost reductions and repeatable productivity. Key clinical assets like REC-4881 and REC…...


markets.ft.com > data > announce > detail

Asahi Kasei Introduces VANTIJ?? SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing??? Company Announcement - FT.com

2+ hour, 9+ min ago   (494+ words) Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing – Company Announcement - FT.com Financial Times Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing GLENVIEW, Ill.--(BUSINESS WIRE)…...


indianpharmapost.com > biopharma > dr-reddys-launches-nivolumab-biosimilar-nivorz-in-india-21853

Dr. Reddy’s launches nivolumab biosimilar NIVORZ in India

2+ hour, 42+ min ago   (322+ words) In-house developed and manufactured biosimilar marks company’s entry into immuno-oncology and aims to improve access to checkpoint inhibitor therapy Dr. Reddy’s Laboratories has launched NIVORZ (nivolumab biosimilar), a biosimilar to Opdivo (nivolumab), in India, marking its entry into the country’s…...